Identification of a six-lncRNA signature based on a competing endogenous RNA network for predicting the risk of tumour recurrence in bladder cancer patients

Zhao, Danfeng; Peng, Qiang; Wang, Lu; Li, Cong; Lv, Yulin; Liu, Yong; Wang, Zhichao; Fang, Ruizhe; Wang, Jiaqi; Liu, Zhongqing; Xu, Wanhai

doi:10.7150/jca.35801



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(1):108-120. doi:10.7150/jca.35801 This issue Cite

Research Paper

Identification of a six-lncRNA signature based on a competing endogenous RNA network for predicting the risk of tumour recurrence in bladder cancer patients

Danfeng Zhao^1,2*, Qiang Peng^1*, Lu Wang^1,2*, Cong Li¹, Yulin Lv^1,2, Yong Liu³, Zhichao Wang¹, Ruizhe Fang¹, Jiaqi Wang^1,2, Zhongqing Liu¹, Wanhai Xu^1,2✉

1. Department of Urology, the Fourth Hospital of Harbin Medical University, Harbin Medical University, Harbin, P. R. China.
2. Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin, P. R. China.
3. Department of Urology, Qitaihe People's Hospital, Qitaihe, P.R. China.
*These authors contributed equally to this work

Citation:

Zhao D, Peng Q, Wang L, Li C, Lv Y, Liu Y, Wang Z, Fang R, Wang J, Liu Z, Xu W. Identification of a six-lncRNA signature based on a competing endogenous RNA network for predicting the risk of tumour recurrence in bladder cancer patients. J Cancer 2020; 11(1):108-120. doi:10.7150/jca.35801. https://www.jcancer.org/v11p0108.htm

Other styles

Abstract

Bladder cancer (BC) is the most common malignancy involving the urinary system, and is characterized by a high recurrence rate. It is important to identify potential lncRNA signatures capable of predicting tumour recurrence risk and assessing recurrence prognosis in BC patients. We extracted data from The Cancer Genome Atlas and identified 381 differentially expressed lncRNAs, 855 mRNAs and 70 miRNAs between non-recurrent and recurrent BC tissues. Subsequently, a competing endogenous RNA (ceRNA) network composed of 29 lncRNAs, 13 miRNAs and 4 mRNAs was established. We used univariate and multivariate Cox regression to analyse the relationship between the 29 lncRNAs and recurrence-free survival (RFS) in BC patients. Six lncRNAs had significant prognostic values, and their cumulative risk score indicated that this 6-lncRNA signature independently predicted RFS in BC patients. We applied a receiver operating characteristic (ROC) analysis to assess the efficiency of our prognostic models. High-risk patients exhibited a poorer prognosis than low-risk patients did. Additionally, the 6-lncRNA signature showed a significant correlation with BC clinicopathological characteristics, which indicates that it could be used for effective risk stratification. The current study provides novel insights into the lncRNA-related ceRNA network and this 6-lncRNA signature may be an independent prognostic factor in predicting the recurrence of BC patients.

Keywords: Bladder cancer, Recurrence risk, Recurrence free survival, LncRNA, ceRNA network

Citation styles

APA

Zhao, D., Peng, Q., Wang, L., Li, C., Lv, Y., Liu, Y., Wang, Z., Fang, R., Wang, J., Liu, Z., Xu, W. (2020). Identification of a six-lncRNA signature based on a competing endogenous RNA network for predicting the risk of tumour recurrence in bladder cancer patients. Journal of Cancer, 11(1), 108-120. https://doi.org/10.7150/jca.35801.

ACS

Zhao, D.; Peng, Q.; Wang, L.; Li, C.; Lv, Y.; Liu, Y.; Wang, Z.; Fang, R.; Wang, J.; Liu, Z.; Xu, W. Identification of a six-lncRNA signature based on a competing endogenous RNA network for predicting the risk of tumour recurrence in bladder cancer patients. J. Cancer 2020, 11 (1), 108-120. DOI: 10.7150/jca.35801.

NLM

CSE

Zhao D, Peng Q, Wang L, Li C, Lv Y, Liu Y, Wang Z, Fang R, Wang J, Liu Z, Xu W. 2020. Identification of a six-lncRNA signature based on a competing endogenous RNA network for predicting the risk of tumour recurrence in bladder cancer patients. J Cancer. 11(1):108-120.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.